Leukemia - Table of Contents alert Volume 27 Issue 8

Advertisement BD FACSCanto™ II: Timeless reliability.  With its proven reliability and consistency, the BD FACSCanto™ II lets you keep work flowing so clinicians can more confidently deliver patient care. For over 40 years we've been making flow cytometry solutions that help make your job easier, your workflow more efficient, and your results more reliable. bdbiosciences.com/go/canto TABLE OF CONTENTS Volume 27, Issue 8 (August 2013) In this issue Concise Review Original Articles Letters to the Editor Corrigenda Also new AOP Advertisement   Just one of many high quality articles Frontiers in Oncology has to offer:  Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models (open access) In this study, Peter Bader and colleagues focus on the principal biological characteristics and engraftment sites of human acute myeloid leukemia (AML) and RMS cells injected via the tail vein in sublethally irradiated NSG mice. Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement SIOP 2013 - 45th Congress of the International Society of Paediatric Oncology 25th-28th September 2013 Hong Kong, China. The largest annual paediatric cancer meeting in the world on all cancer types affecting children, incl. leukemia and brain tumours. Register Now! * Discounts for SIOP members, Residents/Fellows, Nurses, Psychology & Psychosocial professionals, Parents/Survivors. www.kenes.com/siop     Concise Review Top Personalized management of essential thrombocythemia—application of recent evidence to clinical practice Open A Tefferi and T Barbui Leukemia 2013 27: 1617-1620; advance online publication, April 5, 2013; 10.1038/leu.2013.99 Abstract | Full Text Original Articles Top MOLECULAR TARGETS FOR THERAPY A novel therapeutic molecule against HTLV-1 infection targeting provirus A Tanaka, S Takeda, R Kariya, K Matsuda, E Urano, S Okada and J Komano Leukemia 2013 27: 1621-1627; advance online publication, February 15, 2013; 10.1038/leu.2013.46 Abstract | Full Text THERAPY Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies D J DeAngelo, A Spencer, K N Bhalla, H M Prince, T Fischer, T Kindler, F J Giles, J W Scott, K Parker, A Liu, M Woo, P Atadja, K K Mishra and O G Ottmann Leukemia 2013 27: 1628-1636; advance online publication, February 6, 2013; 10.1038/leu.2013.38 Abstract | Full Text ACUTE LEUKEMIAS Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56 Y Saito, K Kaneda, A Suekane, E Ichihara, S Nakahata, N Yamakawa, K Nagai, N Mizuno, K Kogawa, I Miura, H Itoh and K Morishita Leukemia 2013 27: 1637-1649; advance online publication, March 12, 2013; 10.1038/leu.2013.75 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS Cleavage of BCR–ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR–ABL leukemic cells J E Kim, S Yoon, B-R Choi, K P Kim, Y-H Cho, W Jung, D-W Kim, S Oh and D-E Kim Leukemia 2013 27: 1650-1658; advance online publication, February 25, 2013; 10.1038/leu.2013.60 Abstract | Full Text MINIMAL RESIDUAL DISEASE Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia Open A C Logan, B Zhang, B Narasimhan, V Carlton, J Zheng, M Moorhead, M R Krampf, C D Jones, A N Waqar, M Faham, J L Zehnder and D B Miklos Leukemia 2013 27: 1659-1665; advance online publication, February 19, 2013; 10.1038/leu.2013.52 Abstract | Full Text ANIMAL MODELS Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia L C Gillis, D M Berry, M D Minden, C J McGlade and D L Barber Leukemia 2013 27: 1666-1676; advance online publication, February 12, 2013; 10.1038/leu.2013.40 Abstract | Full Text LYMPHOMA Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts S L Locatelli, A Giacomini, A Guidetti, L Cleris, R Mortarini, A Anichini, A M Gianni and C Carlo-Stella Leukemia 2013 27: 1677-1687; advance online publication, January 30, 2013; 10.1038/leu.2013.28 Abstract | Full Text Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype S-Y Tan, S-S Chuang, T Tang, L Tan, Y-H Ko, K-L Chuah, S-B Ng, W-J Chng, K Gatter, F Loong, Y-H Liu, P Hosking, P-L Cheah, B-T Teh, K Tay, M Koh and S-T Lim Leukemia 2013 27: 1688-1696; advance online publication, February 12, 2013; 10.1038/leu.2013.41 Abstract | Full Text MYELOMA Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction P Storti, M Bolzoni, G Donofrio, I Airoldi, D Guasco, D Toscani, E Martella, M Lazzaretti, C Mancini, L Agnelli, K Patrene, S Maïga, V Franceschi, S Colla, J Anderson, A Neri, M Amiot, F Aversa, G David Roodman and N Giuliani Leukemia 2013 27: 1697-1706; advance online publication, January 24, 2013; 10.1038/leu.2013.24 Abstract | Full Text Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety Open A Z Badros, R Vij, T Martin, J A Zonder, L Kunkel, Z Wang, S Lee, A F Wong and R Niesvizky Leukemia 2013 27: 1707-1714; advance online publication, January 31, 2013; 10.1038/leu.2013.29 Abstract | Full Text Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy T Scullen, L Santo, S Vallet, M Fulciniti, H Eda, D Cirstea, K Patel, N Nemani, A Yee, A Mahindra and N Raje Leukemia 2013 27: 1715-1721; advance online publication, February 18, 2013; 10.1038/leu.2013.50 Abstract | Full Text MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia C Jiménez, E Sebastián, M C Chillón, P Giraldo, J Mariano Hernández, F Escalante, T J González-López, C Aguilera, A G de Coca, I Murillo, M Alcoceba, A Balanzategui, M E Sarasquete, R Corral, L A Marín, B Paiva, E M Ocio, N C Gutiérrez, M González, J F San Miguel and R García-Sanz Leukemia 2013 27: 1722-1728; advance online publication, February 28, 2013; 10.1038/leu.2013.62 Abstract | Full Text The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis K A Kocemba, H van Andel, A de Haan-Kramer, K Mahtouk, R Versteeg, M J Kersten, M Spaargaren and S T Pals Leukemia 2013 27: 1729-1737; advance online publication, March 12, 2013; 10.1038/leu.2013.76 Abstract | Full Text Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma S V Rajkumar, V Gupta, R Fonseca, A Dispenzieri, W I Gonsalves, D Larson, R P Ketterling, J A Lust, R A Kyle and S K Kumar Leukemia 2013 27: 1738-1744; advance online publication, March 21, 2013; 10.1038/leu.2013.86 Abstract | Full Text Letters to the Editor Top Recurrent involvement of ring-type zinc finger genes in complex molecular rearrangements in childhood acute myelogeneous leukemia with translocation t(10;11)(p12;q23) S Ghosh, C Bartenhagen, V Okpanyi, M Gombert, V Binder, A Teigler-Schlegel, J Bradtke, S Röttgers, M Dugas and A Borkhardt Leukemia 2013 27: 1745-1748; advance online publication, January 9, 2013; 10.1038/leu.2013.1 Full Text Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas L Miguet, S Lennon, L Baseggio, A Traverse-Glehen, F Berger, N Perrusson, M-P Chenard, A-C Galoisy, A Eischen, C Mayeur-Rousse, A Maar, L Fornecker, R Herbrecht, P Felman, A Van Dorsselaer, C Carapito, S Cianférani and L Mauvieux Leukemia 2013 27: 1748-1750; advance online publication, January 10, 2013; 10.1038/leu.2013.3 Full Text Base-pair resolution DNA methylome of the EBV-positive Endemic Burkitt lymphoma cell line DAUDI determined by SOLiD bisulfite-sequencing Open B Kreck, J Richter, O Ammerpohl, M Barann, D Esser, B S Petersen, I Vater, E M Murga Penas, C A Bormann Chung, S Seisenberger, V Lee Boyd, S Smallwood, H G Drexler, R A F MacLeod, M Hummel, F Krueger, R Häsler, S Schreiber, P Rosenstiel, A Franke and R Siebert Leukemia 2013 27: 1751-1753; advance online publication, January 11, 2013; 10.1038/leu.2013.4 Full Text A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR M F Kaiser, B A Walker, S L Hockley, D B Begum, C P Wardell, D Gonzalez, F M Ross, F E Davies and G J Morgan Leukemia 2013 27: 1754-1757; advance online publication, January 15, 2013; 10.1038/leu.2013.12 Full Text From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome S Bouchet, S Dulucq, J-M Pasquet, V Lagarde, M Molimard and F-X Mahon Leukemia 2013 27: 1757-1759; advance online publication, January 16, 2013; 10.1038/leu.2013.13 Full Text Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts B H Yip, C Vuppusetty, M Attwood, A Giagounidis, U Germing, A A Lamikanra, D J Roberts, J P Maciejewski, P Vandenberghe, C Mecucci, J S Wainscoat, A Pellagatti and J Boultwood Leukemia 2013 27: 1760-1763; advance online publication, January 22, 2013; 10.1038/leu.2013.20 Full Text JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms J Wang, Z Xu, L Liu, R P Gale, N C P Cross, A V Jones, T Qin, X Ai, J Xu, T Zhang, X Sun, Q Li, P Zhang, Y Zhang and Z Xiao Leukemia 2013 27: 1763-1767; advance online publication, January 22, 2013; 10.1038/leu.2013.21 Full Text MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients N Nuber, A Curioni-Fontecedro, S R Dannenmann, C Matter, L von Boehmer, D Atanackovic, A Knuth and M van den Broek Leukemia 2013 27: 1767-1769; advance online publication, February 1, 2013; 10.1038/leu.2013.31 Full Text Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia S E M Herman, P M Barr, E M McAuley, D Liu, A Wiestner and J W Friedberg Leukemia 2013 27: 1769-1773; advance online publication, February 6, 2013; 10.1038/leu.2013.37 Full Text Stromal cell-induced miRNA alteration in chronic lymphocytic leukemia: how a minute and unavoidable cell contamination impairs miRNA profiling J Paggetti, G Berchem and E Moussay Leukemia 2013 27: 1773-1776; advance online publication, February 14, 2013; 10.1038/leu.2013.43 Full Text Mutant DNMT3A in acute myeloid leukemia: guilty of inducing genetic instability? A Zebisch, G Hoefler, F Quehenberger, A Wölfler and H Sill Leukemia 2013 27: 1777-1778; advance online publication, February 18, 2013; 10.1038/leu.2013.48 Full Text Natural history of acute lymphoblastic leukemia in neurofibromatosis type 1 monozygotic twins M Galbiati, A Lettieri, C Micalizzi, S Songia, C Morerio, A Biondi, C Dufour and G Cazzaniga Leukemia 2013 27: 1778-1781; advance online publication, February 21, 2013; 10.1038/leu.2013.55 Full Text Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia L Leanza, L Trentin, K A Becker, F Frezzato, M Zoratti, G Semenzato, E Gulbins and I Szabo Leukemia 2013 27: 1782-1785; advance online publication, February 21, 2013; 10.1038/leu.2013.56 Full Text Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia A M Aalbers, R T Calado, N S Young, C M Zwaan, C Wu, S Kajigaya, E A Coenen, A Baruchel, K Geleijns, V de Haas, G J L Kaspers, T W Kuijpers, D Reinhardt, J Trka, M Zimmermann, R Pieters, V H J van der Velden and M M van den Heuvel-Eibrink Leukemia 2013 27: 1786-1789; advance online publication, February 21, 2013; 10.1038/leu.2013.57 Full Text Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity E D Warlick, Q Cao and J Miller Leukemia 2013 27: 1789-1791; advance online publication, February 28, 2013; 10.1038/leu.2013.61 Full Text Corrigenda Top Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression S Bomken, L Buechler, K Rehe, F Ponthan, A Elder, H Blair, C M Bacon, J Vormoor and O Heidenreich Leukemia 2013 27: 1792; 10.1038/leu.2013.113 Full Text Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas H Kato, K Yamamoto, Y Oki, S Ine, H Taji, D Chihara, Y Kagami, M Seto and Y Morishima Leukemia 2013 27: 1792; 10.1038/leu.2013.134 Full Text Advertisement Hot off the press!! Read this recent study published in British Journal of Cancer:  The benefits and harms of breast cancer screening: an independent review  Like what you see? Spread the word. [Twitter]  [Facebook]  Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.